W. Werbel

Cameron R. Wolfe, T. Quinn, D. Segev, 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

National Landscape of HIV+ Deceased Organ Donors in the United States.

Cameron R. Wolfe, C. Petropoulos, T. Quinn, 2021, Clinical Infectious Diseases.

mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients

D. Segev, R. Ghobrial, A. Tobian, 2022, American Journal of Transplantation.

Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS–CoV‐2 Messenger RNA Vaccination

D. Segev, D. Geetha, I. Barbur, 2021, Arthritis & rheumatology.

A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients

J. Blankson, S. Klein, D. Segev, 2021, American Journal of Transplantation.

Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients

D. Segev, A. Massie, J. Alejo, 2022, JAMA network open.

Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS‐CoV‐2 vaccines in solid organ transplant recipients: A case series

D. Segev, D. Warren, A. Massie, 2022, Clinical transplantation.

Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination

D. Segev, D. Warren, A. Massie, 2022, American Journal of Transplantation.

SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients

R. Higgins, P. Shah, D. Segev, 2021, The Journal of Heart and Lung Transplantation.

Perivaccination Antimetabolite Hold and Third Dose of SARS-CoV-2 Vaccine in Lung Transplant Recipients: Preliminary Report.

P. Shah, D. Segev, R. Avery, 2022, Transplantation.

Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients.

D. Segev, D. Warren, A. Massie, 2022, Transplantation.

SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19

D. Segev, A. Massie, R. Avery, 2021, Transplantation.

Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease

D. Segev, M. Lazarev, A. Parian, 2022, The American journal of gastroenterology.

Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

D. Segev, M. Lazarev, A. Parian, 2022, Clinical Gastroenterology and Hepatology.

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients

D. Segev, D. Warren, A. Massie, 2023, American Journal of Transplantation.

Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease

Ami A. Shah, J. Albayda, D. Segev, 2022, Rheumatology.

Antibody response to SARS-CoV-2 messenger RNA vaccines in liver transplant recipients.

D. Segev, A. Massie, A. Tobian, 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Antibody response to a third dose of SARS‐CoV‐2 vaccine in heart and lung transplant recipients

D. Segev, D. Warren, A. Massie, 2022, Clinical transplantation.

Incidence and Severity of COVID-19 Among Vaccinated Solid Organ Transplant Recipients During the Omicron Wave.

D. Segev, D. Warren, A. Massie, 2022, Transplantation.

Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics

Chiung-Yu Huang, P. Shah, C. Merlo, 2021, Transplantation direct.

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.

D. Segev, J. Bailey, C. Durand, 2021, AIDS.

Immunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV

D. Segev, K. Gebo, J. Bailey, 2023, Journal of acquired immune deficiency syndromes.

Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update

D. Segev, D. Warren, A. Massie, 2022, Transplantation.

Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series

Ami A. Shah, J. Albayda, D. Segev, 2022, Annals of the Rheumatic Diseases.

A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients

J. Blankson, S. Klein, D. Segev, 2021, American Journal of Transplantation.

Antibody Response to Severe Acute Respiratory Syndrome‐Coronavirus‐2 Messenger RNA Vaccines in Liver Transplant Recipients

D. Segev, A. Massie, A. Tobian, 2021, Liver Transplantation.

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

D. Segev, A. Massie, L. Christopher‐Stine, 2022, The Lancet Rheumatology.

COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge

P. Shah, D. Segev, R. Avery, 2022, Transplantation.

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

D. Segev, B. Boyarsky, W. Werbel, 2021, BMC Cancer.

Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases

D. Segev, A. Massie, L. Christopher‐Stine, 2021, Annals of the Rheumatic Diseases.

Persistent SARS-CoV-2–specific immune defects in kidney transplant recipients following third mRNA vaccine dose

S. Klein, D. Segev, D. Warren, 2023, American Journal of Transplantation.

Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series

Ami A. Shah, D. Segev, A. Massie, 2021, Annals of the Rheumatic Diseases.

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients

D. Segev, D. Warren, A. Massie, 2023, American Journal of Transplantation.

Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients

D. Segev, D. Warren, A. Massie, 2021, Transplantation.

Shared and Data‐Driven Decision‐Making with Transplant Recipients About COVID‐19 Vaccination Is Crucial

D. Segev, Alexandra T. Strauss, W. Werbel, 2022, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Incidence of SARS‐CoV‐2 infection among unvaccinated US adults during the Omicron wave

M. Makary, D. Segev, A. Massie, 2022, medRxiv.

Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients

J. Blankson, D. Segev, N. Rouphael, 2023, JCI insight.

Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk

D. Segev, A. Massie, A. Tobian, 2023, Clinical transplantation.

Persistent SARS-CoV-2–specific immune defects in kidney transplant recipients following third mRNA vaccine dose

S. Klein, D. Segev, D. Warren, 2023, American Journal of Transplantation.

Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?

M. Sundaram, Varun K. Phadke, Sonali D. Advani, 2023, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients

D. Segev, D. Warren, A. Massie, 2022, Transplantation.

Improved humoral immunogenicity with mRNA‐1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses

D. Segev, D. Warren, A. Massie, 2022, Clinical transplantation.

Impact of Seasonal Coronavirus Antibodies on SARS-CoV-2 Vaccine Responses in Solid Organ Transplant Recipients

J. Blankson, D. Segev, Y. Eby, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Humoral and Cellular Immune Response to a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients Taking Belatacept.

J. Blankson, D. Segev, D. Warren, 2022, Transplantation.

Antibody Kinetics after Three Doses of SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

D. Segev, M. Lazarev, A. Parian, 2023, Medicina.

210.5: Differential Immunogenicity of mRNA-1273 Versus BNT162b2 as a Third Vaccine Dose for Solid Organ Transplant Recipients Seronegative After Two BNT162b2 Doses.

D. Segev, D. Warren, A. Massie, 2022, Transplantation.

Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?

M. Sundaram, Varun K. Phadke, Sonali D. Advani, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibody Response to Severe Acute Respiratory Syndrome‐Coronavirus‐2 Messenger RNA Vaccines in Liver Transplant Recipients

D. Segev, A. Massie, A. Tobian, 2021, Liver Transplantation.